Chemotherapy and G-CSF for Mobilization

NCT ID: NCT03442673

Last Updated: 2025-03-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 137 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-17
• Study Completion Date: 2024-05-01

Brief Summary

This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in myeloma patients.

Detailed Description

Background and Rationale High-dose chemotherapy (HDCT) with melphalan and autologous stem cell transplantation (ASCT) remains an integral component of the myeloma treatment algorithm for patients considered eligible for the procedure, nowadays performed in myeloma patients up to the age of 75 years. Until the advent of the novel agents, the initial therapy regimens commonly used were vincristine, doxorubicin, and dexamethasone (VAD) or single-agent dexamethasone, both of which shared the advantage of having little impact on stem cell mobilization and collection. Previous studies had shown that alkylating agents can potentially affect the stem cell pool and thus interfere with the ability to collect adequate numbers of stem cells. However, VAD is no longer uses nowadays, whereas current lenalidomide-containing combinations significantly affect stem cell collection. .In Switzerland, the combination of non-myeloablative chemotherapy with vinorelbine or gemcitabine and G-CSF is the current standard procedure. With the predominant use of bortezomib during induction treatment more patients have pre-existing neurotoxicity. Vinorelbine can aggravate this problem. Recently data have shown that a mobilization with gemcitabine together with G-CSF is safe and effective in myeloma patients. Whether chemotherapy is mandatory at all to achieve the same reliable and cost-effective mobilization is currently unknown. The investigators therefore consider that a direct comparison between vinorelbine/gemcitabine and G-CSF versus G-CSF alone is justified.

Objective:

The primary objective is to show non-inferiority of cytokine stimulation with G-CSF compared to chemotherapy stimulation with vinorelbine (or gemcitabine) together with G-CSF for the mobilization of autologous stem cells in myeloma patients in first remission.

Study Duration:

The anticipated total study duration is 42 months.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CG (Chemotherapy/G-CSF) - Regime

Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.

Group Type: ACTIVE_COMPARATOR

Vinorelbine

Intervention Type: DRUG

Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells

Gemcitabine

Intervention Type: DRUG

Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells

G-CSF

Intervention Type: DRUG

Cytokine stimulation with G-CSF for mobilization of autologous stem cells

G (G-CSF) - Regime

G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.

Group Type: EXPERIMENTAL

G-CSF

Intervention Type: DRUG

Cytokine stimulation with G-CSF for mobilization of autologous stem cells

Interventions

Vinorelbine

Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells

Intervention Type: DRUG

Gemcitabine

Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells

Intervention Type: DRUG

G-CSF

Cytokine stimulation with G-CSF for mobilization of autologous stem cells

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Myeloma or amyloidosis patients after standard first-line induction treatment. (Additional induction regimens in refractory myeloma patients are allowed)
• Patients must be considered being clinically fit for subsequent consolidation with high-dose melphalan-based chemotherapy with autologous stem cell support.
• Patients must be aged ≥18 years.
• Female patients of child-bearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to study treatment mobilisation, and they must implement adequate measures (hormonal treatment p.o. or i.m., intra uterine surgical devices, or latex condoms) to avoid pregnancy during study treatment and for additional 12 months.
• Patients must have given voluntary written informed consent

Exclusion Criteria

• Patients with concurrent other malignant disease can be included, but previous treatment for other malignancies must have been terminated at least 2 months before registration. Endocrine treatment (such as for breast cancer) is allowed.
• Pregnancy or lactating female patients.
• The use of any anti-cancer investigational agents within 14 days prior to the expected start of trial treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Insel Gruppe AG, University Hospital Bern

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Barbara Jeker, MD

Role: STUDY_CHAIR

Department for Medical Oncology University Hospital/Inselspital 3010 Bern Switzerland

Locations

Department for Medical Oncology University Hospital/Inselspital

Bern, , Switzerland

Countries

Switzerland

References

Jeker B, Thalmann L, Bacher U, Nilius H, Rhyner G, Sokler M, Soltermann S, Winkler A, Vorburger C, Daskalakis M, Hoffmann M, Pabst T. Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial. Bone Marrow Transplant. 2025 Mar;60(3):270-276. doi: 10.1038/s41409-024-02468-z. Epub 2024 Nov 15.

Reference Type: DERIVED

PMID: 39548306 (View on PubMed)

Other Identifiers

MOCCCA-Trial

Identifier Type: -

Identifier Source: org_study_id